Although the use of glucocorticoids as a long term maintenance therapy for cancer patients is less than ideal, a therapy capable of inducing CDKN1C expression is an attractive strategy not only because of strong growth inhibition but also because somatic inactivating mutations of CDKN1C are rare. This evidence concerns the gene CDKN1C and cancer.